US/UK/Canada

Share

Contacts

  • Sarah Fredriksson

    CEO


    C/O HETCH AB Redaregatan 48 SE-252 36 Helsingborg Sweden
    + 46 (0)70 261 4575
    http://www.aqilion.com

    • Quotes

    Our discovery team has been working with several interesting drug targets during the last two years, with the aim to select a new preclinical program. It is exiting to be able nominate PKCtheta and to leverage experiences and successes from Aqilion’s other preclinical and clinical kinase inhibitor programs
    Sarah Fredriksson, CEO of Aqilion.
    It is very pleasing and strategically important that we have appointed Gustaf as the new CFO. He will bring broad and relevant experience and expertise to enhance the Aqilion’s finance function and contribute to the company's future financing. At the same time, I would like to take the opportunity to thank Torgeir Vaage for his contributions to the company over many years.
    Sarah Fredriksson, CEO of Aqilion
    We thank our shareholders for their support. The capital injection will primarily be used for our early research projects with focus on new innovative treatments for chronic inflammatory diseases where there is a pronounced medical need, but only few or no treatments
    Sarah Fredriksson, CEO of Aqilion
    With our new Scientific Advisory Board, three internationally renowned scientists are joining our team as advisors. Both their outstanding scientific and clinical expertise and an active network of researchers in EoE will be invaluable for Aqilion
    Sarah Fredriksson, CEO of Aqilion
    We are delighted and proud to announce this collaboration with Merck as it validates our business strategy of generating highly innovative discovery projects in combination with pro-active business development and early deal-making. We are looking forward to working with Merck as this will speed up the process of bringing novel effective treatments to conditions with high unmet medical needs.
    Sarah Fredriksson, CEO of Aqilion
    Pick a time period -
    Tags ( Active)

    Aqilion presents results from study of biomarkers in patients with Eosinophilic esophagitis (EoE) at the Digestive Disease Week conference on May 3-6

    AQILION AB (publ) AQILION AB (publ) presents results from a study conducted by the Company together with Professor Evan Dellon after the research group's abstract was approved at this year's Digestive Disease Week, May 3-6, in San Diego.The study aims to investigate markers in the blood of patients with Eosinophilic esophagitis (EoE) in order to find new methods to diagnose and follow up treatment in the future.The aim of the study was to explore proteins in the blood of EoE patients, with a focus on variability at baseline, change with treatment, and whether pre-treatment plasma proteins

    Aqilion carries out a rights issue of approximately SEK 26.8 million

    THE INFORMATION IN THIS PRESS RELEASE IS NOT INTENDED FOR RELEASE,  DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE,  DISTRIBUTION  OR PUBLICATION WOULD VIOLATE ANY APPLICABLE LAWS OR REGULATIONS.The Board of Directors of Aqilion AB (publ) ("Aqilion" or the "Company") has on 11 February 2025, based on the authorization granted by the Annual General Meeting on 10 June 2024, resolved to carry out

    Aqilion Resumes Development of its TAK1-Program

    AQILION AB (publ) announces that the Company has resumed development of the its TAK1 program as the company has  regained the control and ownership of the program. After reviewing and analysing the complete data package, Aqilion decided to recommence the development of the program. The TAK1 mechanism is a key regulator of inflammation and the objective is to develope a new treatment for severe diseases caused by chronic inflammation and dysfunctional immune reactions.The TAK1 mechanism is a central biological switch for several central inflammatory processes. By dampening its activity,

    The Nomination Committee has been appointed for the Aqilion Annual General Meeting 2025

    Aqilion AB (publ) hereby announces that the Nomination Committee for the 2025 Annual General Meeting has been appointed and consists of:•    Hites Jina, appointed by the shareholder LMK Forward AB•    Linus Wiebe, appointed by the shareholder Fåhraeus Start Up and Growth AB•    Katarina Berggren, appointed by the shareholder Aktiebolaget Grenspecialisten•    Philip Jansson, appointed by the shareholder Länsförsäkringar Göteborg och Bohuslän  The Nomination Committee has been appointed in accordance with guidelines established at the 2024 Annual General Meeting. As of September 30,

    Aqilion presents new results from the AQ312 program (oral Ahr agonist) during UEG Week in Vienna

    AQILION AB (publ) is developing the anti-inflammatory drug candidate AQ312 for the treatment of ulcerative colitis, and presents new results from the Aqilion preclinical development program at the United European Gastroenterology (UEG) Week in Vienna.Wayne Russell, Senior Director Translational Biology and Innovation, presents new preclinical data describing the drug candidate AQ312 in several gastrointestinal disease models. The presentation will take place during UEG Week 2024 in Vienna on October 12-15 .   Aqilion is developing the drug candidate AQ312, an

    Resolutions from AQILION AB (publ) Annual General Meeting 2024

    Helsingborg, June 10, 2024 – AQILION AB (publ) held its Annual General Meeting today, at which the meeting decided in accordance with the proposals presented. For more detailed information on the content of the resolutions, please see the full notice to the Annual General Meeting, which is available on Aqilion's website, www.aqilion.comAdoption of income statements and balance sheetsThe Annual General Meeting approved the income statement and balance sheet included in the annual report for the business year 2023. The Annual General Meeting decided that the entire amount at the disposal of

    Aqilion to present results at scientific events

    AQILION AB (publ) will present updates on the Company's progress and scientific results at two different scientific conferences in May. The presentations will cover the pipeline programs AQ280 for the treatment of eosinophilic esophagitis and AQ312 for the treatment of ulcerative colitis.Johan Lund, CSO, will present Aqilion's pipeline with a special focus on the pipeline programs AQ280 and AQ312 at the 20th Annual Conference of International Drug Discovery and Science technology (IDDST) in Osaka, Japan, May 22-24, .   Anneli Tinnerholm,

    Aqilion expands its pipeline

    AQILION AB (publ) announces an expansion of its pipeline through the nomination of PKCtheta as the target of a new immunology project.Aqilion’s aims at the discovery and development of differentiated and effective treatments for autoimmune and inflammatory diseases. The PKCtheta kinase plays a critical role in T-cell receptor signaling and is believed to be centrally involved in the pathogenesis of T-cell mediated inflammatory and autoimmune diseases e.g. ulcerative colitis and rheumatoid arthritis. PKCtheta has garnered significant attention from the pharmaceutical industry and, using our

    Notice of Annual General Meeting in AQILION AB (publ)

    The shareholders of AQILION AB (publ), 556623-2095, are hereby invited to the Annual General Meeting Monday, June 10, 2024  This is a translation of the Swedish original. In the event of any discrepancy between this translation and the Swedish original, the Swedish version shall prevail. Welcome to the Aqilion Annual General Meeting, which will be held on Monday 10 June 2024 in the Company's premises, the PRISMA building, visiting address Henckels torg 3 in Helsingborg. 16:45 – 17:00 p.m. Registration17:00 p.m.  Annual General Meeting convened Right to participate and

    Aqilion presents Nomination Committee for the 2024 Annual General Meeting

    The Nomination Committee for the 2024 Annual General Meeting has been appointed and comprises the following members:• Christian Ewe, appointed by the shareholder LMK Forward AB • Linus Wiebe, appointed by the shareholder Fåhraeus Start Up and Growth AB • Katarina Berggren, appointed by the shareholder Grenspecialisten AB   The members appoint the Chairman among themselves.   The Nomination Committee shall prepare proposals for the 2024 Annual General Meeting regarding the Chairman of the meeting, election of Board members and Chairman of the Board, the fees to be paid

    Aqilion appoints Gustaf Albèrt as new CFO

    AQILION (publ) has appointed Gustaf Albèrt as the new CFO. Gustaf has solid financial experience from both smaller and larger listed groups and has worked as CFO in a listed environment within the life science industry. As CFO, he will be part of the Group management and report to the CEO.In connection with the recruitment of Gustaf Albèrt, Torgeir Vaage, former VP and CFO, is leaving Aqilion.   "It is very pleasing and strategically important that we have appointed Gustaf as the new CFO. He will bring broad and relevant experience and expertise to enhance the Aqilion’s finance

    Aqilion reports positive results from the ARIA-1 Phase 1 study in healthy subjects

    · The drug candidate AQ280, an oral selective JAK1 inhibitor, was well tolerated, and the achieved single and multidose exposure is in line with estimates of a therapeutically effective range based on preclinical models · Pharmacokinetic data supports once daily dosing · Pharmacodynamic biomarker changes are consistent with JAK1 inhibition with no observed signs of JAK2 inhibition at the achieved exposuresAQILION (publ) reports positive results from its Phase 1 study ARIA-1 in healthy volunteers with the drug candidate AQ280, a selective proprietary JAK1 inhibitor, being developed as

    Notice of Annual General Meeting in AQILION AB (publ)

    The shareholders of AQILION AB (publ), 556623-2095, are hereby invited to the Annual General Meeting Thursday, June 1, 2023 Welcome to the Aqilion Annual General Meeting, which will be held on Thursday 1 June 2023 in the Company's premises, the PRISMA building, visiting address Henckels torg 3 in Helsingborg. 16:45 – 17:00 p.m.              Registration17:00 p.m.                            Annual General Meeting convened   Right to participate and registration Shareholders who are registered in the register of shareholders maintained by Euroclear Sweden AB on May 24, 2023

    Aqilion appoints Scientific Advisory Board

    Aqilion today announces the formation of a Scientific Advisory Board with three key appointments:  Dr. Luc Michel Biedermann, Professor Albert J Bredenoord and Professor Evan S. Dellon. The Scientific Advisory Board will work closely with Aqilion’s management in the development of the company's Regulus program in preparation for planning Phase 2 trials in patients with the inflammatory disease Eosinophilic Esophagitis (EoE).Within the Regulus program, Aqilion is developing the drug candidate AQ280, a selective JAK-1 inhibitor, as a potential oral treatment for EoE, an allergic disease of

    Aqilion announces pre-clinical licensing and strategic research collaboration agreement with Merck

    AQILION AB (“Aqilion”) today announced an exclusive license and strategic research collaboration with Merck to discover, develop and commercialize small molecule inhibitors of the transforming growth factor-β-activated kinase 1 (TAK1) protein. Merck will make an upfront cash payment of EUR 10 million to Aqilion. In addition, Aqilion is eligible to receive potential development and commercialization milestones up to over EUR 950 million and tiered royalties on worldwide net sales.The collaboration builds on Aqilion's extensive experience and know-how in the discovery of selective TAK1

    Aqilion presents Nomination Committee for the 2023 Annual General Meeting

    The Nomination Committee for the 2023 Annual General Meeting has been appointed and comprises the following members: · Christian Ewe, appointed by the shareholder LMK Forward AB · Linus Wiebe, appointed by the shareholder Fåhraeus Start Up and Growth AB · Katarina Berggren, appointed by the shareholder Grenspecialisten AB The members appoint the Chairman among themselves. The Nomination Committee shall prepare proposals for the 2023 Annual General Meeting regarding the Chairman of the meeting, election of Board members and Chairman of the Board, the fees to be paid to the

    Aqilion has completed a rights issue

    AQILION AB (publ) announces today that the company has completed a rights issue with preferential rights for existing shareholders. The company will thus receive SEK 30.5 million after issue costs. The rights issue was carried out as an issue of units. Each unit contains four (4) shares and two (2) warrants of the subscription series TO1. In addition to the initial issue, the company may, subject to full exercise of share warrants of series TO1, receive an additional amount of approximately SEK 20.2 million. Share warrants of series TO1 have an exercise period February - March 2023.

    Aqilion starts Phase 1 clinical trial with drug candidate AQ280 for chronic inflammatory diseases

    AQILION AB (publ) announces today that the Phase 1 clinical safety study on the drug candidate AQ280 on healthy volunteers has started. The substance AQ280, part of the company’s Regulus development program, is a super selective JAK1 small molecule inhibitor that is under development for indications within chronic inflammatory diseases. Aqilion has thus reached a very important milestone as the company has managed to take the big step from preclinical phase to clinical Phase 1.  The Phase 1 clinical trial, ARIA-1, will include 64 healthy volunteers. The purpose of the study is to

    Aqilion resolves on issue in kind

    AQILION AB (publ) is announcing today that the company’s Board of Directors has resolved on an issue in kind in accordance with the acquisition of the Regulus program from LEO Pharma at the end of 2021. The Board was authorized to carry out such a resolution by the Annual General Meeting on June 18, 2021. Under the agreement with LEO Pharma, Aqilion is to pay a final instalment for the acquisition of the Regulus program when the Phase I clinical trial is approved by issuing 221,527 Aqilion shares to LEO Pharma. The Board has therefore resolved on the issue today according to the

    Aqilion strengthens its operational team in clinical development prior to planned Phase I study with drug candidate for inflammatory diseases

    Aqilion announced today that the company has recruited Anneli Tinnerholm to be responsible for Clinical Operations and for project management of the company’s Regulus program. The goal for Regulus is to start a Phase I clinical trial during the second half of 2022 with the drug candidate AQ280 as a potential treatment for eosinophilic esophagitis (EoE), an inflammatory disease of the esophagus. Anneli has solid experience of clinical development and has been active in clinical drug discovery for the past ten years. Anneli Tinnerholm earned a Bachelor of Medical Science in Medical Biology

    Aqilion publishes the Annual Report for 2021

    AQILION AB (publ) hereby announces that the Swedish version of the 2021 Annual Report has been published. The Annual Report, which is attached in Swedish, can also be downloaded from the company’s website . An English translation of the Annual Report is estimated to become available on the website no later than in the week commencing June 13, 2022. For more information, please contact:Sarah Fredriksson, CEO, AQILION AB, + 46 (0)70 261 4575, sarah.fredriksson@aqilion.com About AqilionAqilion is a biotech

    Aqilion strengthens its pipeline with a drug candidate in chronic inflammatory bowel diseases, IBD

    Aqilion has nominated Girtab, a program from the company’s research activities, for further preclinical and clinical development. The goal of Girtab is to develop a new treatment for chronic inflammatory bowel diseases. Girtab complements Aqilion’s pipeline well and strengthens the company’s strategic focus on drug targets and programs with great potential in inflammatory diseases. The development of Girtab has come so far that there is now a clinical drug candidate, AQ312, to be tested in safety studies in a preclinical development program. In parallel, the development of a dosage form

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media

    Rss